Download S. IN THE SENATE OF THE UNITED STATES 114 CONGRESS

BOM16218
S.L.C.
114TH CONGRESS
2D SESSION
S. ll
To amend the market name of genetically altered salmon in the United
States, and for other purposes.
IN THE SENATE OF THE UNITED STATES
llllllllll
Ms. MURKOWSKI (for herself, Ms. CANTWELL, and Mr. SULLIVAN) introduced
the following bill; which was read twice and referred to the Committee
on llllllllll
A BILL
To amend the market name of genetically altered salmon
in the United States, and for other purposes.
1
Be it enacted by the Senate and House of Representa-
2 tives of the United States of America in Congress assembled,
3
4
SECTION 1. SHORT TITLE.
This Act may be cited as the ‘‘Genetically Engineered
5 Salmon Labeling Act’’.
6
7
SEC. 2. PURPOSES.
It is the purpose of this Act to—
8
(1) ensure that consumers in the United States
9
can make informed decisions when purchasing salm-
10
on; and
BOM16218
S.L.C.
2
1
2
(2) authorize an independent scientific review
of—
3
(A) the possible effects of genetically engi-
4
neered salmon on wild salmon stocks; and
5
(B) the Food and Drug Administration’s
6
approval of genetically engineered salmon for
7
human consumption.
8
SEC. 3. MARKET NAME FOR GENETICALLY ENGINEERED
9
10
SALMON.
(a) IN GENERAL.—Notwithstanding any other provi-
11 sion of law, for purposes of applying the Federal Food,
12 Drug, and Cosmetic Act (21 U.S.C. 301 et seq.), the ac13 ceptable market name of any salmon that is genetically
14 engineered shall include the words ‘‘Genetically Engi15 neered’’ or ‘‘GE’’ prior to the existing acceptable market
16 name.
17
(b) DEFINITION.—For purposes of this section, salm-
18 on is genetically engineered if it has been modified by re19 combinant DNA (rDNA) techniques, including the entire
20 lineage of salmon that contain the rDNA modification.
21
22
23
SEC. 4. THIRD-PARTY REVIEW OF CERTAIN SALMON APPROVAL.
(a) REVIEW.—The Secretary of Health and Human
24 Services shall ensure that an independent scientific organi25 zation conducts a review of and submits a report on the
BOM16218
S.L.C.
3
1 environmental assessment that was carried out by the
2 Food and Drug Administration in support of an approval
3 of a new animal drug application related to AquAdvantage
4 Salmon, dated November 12, 2015. In arranging for the
5 review, the Secretary shall ensure that the independent
6 scientific organization will conduct its own assessment of
7 the environmental impacts of approving the application,
8 taking into account the impact of AquAdvantage Salmon
9 on wild stocks of salmon and related wild ecosystems.
10
(b) SECOND ENVIRONMENTAL ASSESSMENT.—On re-
11 ceipt of the report under subsection (a), the Secretary
12 shall require the Food and Drug Administration to con13 duct a second environmental assessment with respect to
14 approval of the application described in subsection (a).
15 The Administration shall take into account the findings
16 in the report in conducting the second environmental as17 sessment.